公开(公告)号：US20210121539A1

公开(公告)日：2021-04-29

申请号：US17257764

申请日：2019-07-04

Applicant: LEMPO THERAPEUTICS LTD ,  RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Anat KAHANA ,  Rotem VOLKMAN ,  Ben Zion GARTY ,  Daniel OFFEN

IPC: A61K38/46 ,  A61K35/28 ,  A61K31/7105 ,  C12N15/90 ,  A61P37/06 ,  A61P25/28

Abstract: The present invention relates to methods of modulating the expression and/or activity of Myeloperoxidase (MPO) in a mammalian subject, by modulating ex vivo and/or in vivo MPO levels and/or activity in undifferentiated bone marrow (BM) cells of the subject. The invention further provide therapeutic methods and compositions for treating MPO-related disorders.

公开(公告)号：US20210214699A1

公开(公告)日：2021-07-15

申请号：US17142072

申请日：2021-01-05

Applicant: LEMPO THERAPEUTICS LTD ,  RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Anat KAHANA ,  Rotem VOLKMAN ,  Ben Zion GARTY ,  Daniel OFFEN

IPC: C12N9/22 ,  C12N15/113 ,  C12N5/077

Abstract: The present invention relates to methods of modulating the expression and/or activity of Myeloperoxidase (MPO) in a mammalian subject, by modulating ex vivo and/or in vivo MPO levels and/or activity in undifferentiated bone marrow (BM) cells of the subject. The invention further provides therapeutic methods and compositions for treating MPO-related disorders.

公开(公告)号：US20240398839A1

公开(公告)日：2024-12-05

申请号：US18694614

申请日：2022-09-22

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Daniel OFFEN ,  Nataly YOM-TOV

IPC: A61K31/00 ,  A61K47/54

Abstract: Provided is a cannabinoid-phospholipid conjugate where the cannabinoid is covalently linked, via a cleavable linker, to a polar head group of the phospholipid. Also provided is a method of obtaining the conjugate, the method comprising (a) reacting the phospholipid (PL) dissolved in an organic solvent with maleic anhydride (MA) to obtain PL-MA intermediate; and (b) reacting said PL-MA intermediate with the cannabinoid in the presence of a carboxyl activating agent and an esterification agent to obtain a reaction mixture comprising said conjugate. Uses of the conjugate are also disclosed.

公开(公告)号：US20240245720A1

公开(公告)日：2024-07-25

申请号：US18564356

申请日：2022-05-25

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Daniel OFFEN ,  Nataly YOM-TOV

IPC: A61K31/785 ,  A61K9/50 ,  A61K9/51 ,  B82Y5/00

CPC classification number: A61K31/785 ,  A61K9/5068 ,  A61K9/5146 ,  A61K9/5161 ,  B82Y5/00

Abstract: The present disclosure provides a composition comprising an extracellular vesicle (EV) associated with an active agent and a polymer, wherein said polymer carries at least one positively charged moiety or has at least one positive pole and said active agent carries, independently, at least one negatively charged moiety or has at least one negative pole; and wherein said polymer and said active agent are present at a positive to negative charge or pole ratio of at least 2. A preferred example relates to a composition wherein the polymer is polyethyleneimine, the agent is a nucleic acid and the EV is an exosome. The present disclosure also provides methods for obtaining the composition and uses of the composition.

公开(公告)号：US20190010130A1

公开(公告)日：2019-01-10

申请号：US16066697

申请日：2017-06-13

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Gerardo Zelmar LEDERKREMER ,  Julia LEITMAN ,  Hagit EIGER ,  Daniel OFFEN ,  Javier GANZ ,  MOshe PORTNOY

IPC: C07D239/42

Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

公开(公告)号：US20230115463A1

公开(公告)日：2023-04-13

申请号：US17959327

申请日：2022-10-04

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Daniel OFFEN ,  Felix BENNINGER ,  Nataly YOM TOV

IPC: A61K47/54 ,  A61K9/127 ,  A61K35/28 ,  A61K31/05 ,  A61P31/00 ,  A61P25/28 ,  A61P25/08

Abstract: Compositions comprising a cell-derived particle associated with Cannabidiol (CBD), and uses thereof in treating medical conditions that can benefit from Cannabidiol (CBD) are provided.

公开(公告)号：US20210361717A1

公开(公告)日：2021-11-25

申请号：US17394008

申请日：2021-08-04

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Daniel OFFEN ,  Nisim PERETS

IPC: A61K35/28 ,  A61P25/28 ,  A61P25/18 ,  A61K9/00 ,  A61K9/127

Abstract: A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells.

公开(公告)号：US20150284793A1

公开(公告)日：2015-10-08

申请号：US14677068

申请日：2015-04-02

Applicant: Ramot at Tel-Aviv University Ltd. ,  Bar-IIan University

Inventor： Daniel OFFEN ,  Ran Barzilay ,  Erez Levanon ,  Khen Khermesh-Shostak

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/16 ,  G01N2800/302

Abstract: Methods and kits for diagnosing schizophrenia are disclosed. The diagnostic method comprises analyzing in a biological sample of a subject a level of A-to-I RNA editing of at least one CNS-expressed gene as set forth in Table 1, wherein an amount of the A-to-I RNA editing of the at least one gene below a predetermined level is indicative of schizophrenia in the subject.

Abstract translation: 公开了用于诊断精神分裂症的方法和试剂盒。 该诊断方法包括在受试者的生物样品中分析如表1所示的至少一种CNS表达基因的A至I RNA编辑水平，其中A至I RNA编辑的量 低于预定水平的至少一种基因表明受试者中的精神分裂症。

公开(公告)号：US20140154222A1

公开(公告)日：2014-06-05

申请号：US14173846

申请日：2014-02-06

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Daniel OFFEN ,  Merav Bahat-Stromza ,  Eldad Melamed

IPC: C12N5/077

CPC classification number: C12N5/0669 ,  C12N5/0622 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/40 ,  C12N2506/1353

Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.

Abstract translation: 提供分离的人细胞及其群体，其包含至少一种星形细胞表型和至少一种间充质干细胞表型，其中间质干细胞表型不是星形细胞表型。

公开(公告)号：US20200331865A1

公开(公告)日：2020-10-22

申请号：US16920710

申请日：2020-07-05

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Gerardo Zelmar LEDERKREMER ,  Julia LEITMAN ,  Hagit EIGER ,  Daniel OFFEN ,  Javier GANZ ,  Moshe PORTNOY

IPC: C07D239/42 ,  A61K45/06 ,  A61K31/505 ,  A61P25/00

Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.